Only one medication , sodium oxybate, continues to be approved, has a high level of evidence of sustained efficacy intended for the treatment of cataplexy, and should be considered a first-line therapy

Only one medication , sodium oxybate, continues to be approved, has a high level of evidence of sustained efficacy intended for the treatment of cataplexy, and should be considered a first-line therapy. of gamma-hydroxybutyrate. Clinical trial evidence of its efficacy and safety in cataplexy is robust, and it is hypothesized that its therapeutic effects may occur through gamma-aminobutyric acidity receptor type B-mediated effects at noradrenergic, dopaminergic, and thalamocortical neurons. Additional possible mechanisms intended for cataplexy therapy suggested by preliminary research include antagonism from the histamine H3autoreceptor with pitolisant and intravenous immunoglobulin therapy for degeneration of the presumed autoimmune-mediated hypocretin/orexin cell loss. Further research and development of therapeutic approaches to cataplexy are needed. Keywords: cataplexy, narcolepsy, treatment, sodium oxybate, antidepressants, emerging therapies == Cataplexy: definition and characteristics == Cataplexy is defined as episodes of sudden, transient loss of voluntary muscle tone (usually bilateral, but case reports have recognized unilateral cases1) triggered by strong emotions. While laughter is the most typical trigger, other triggers include happiness, elation, fright, anger, startle, stress and, much less frequently, pain and orgasm, although episodes may also occur spontaneously. 24Episodes are typically brief, generally enduring <2 minutes, followed by rapid come back of normal muscle tone/function, and range from mild or barely noticeable to severe, with total postural collapse. While any or all voluntary muscles can be affected (with the exception from the diaphragm and the extraocular muscles of the eye), patients remain conscious and continue to breathe and to move their eyes. 3The most common manifestations are neck weakness, causing head drop; partial or total ptosis; facial weakness with sagging from the jaw with or without dysarthria; and trembling or buckling from the knees. 2, 5, 6Positive motor symptoms such as muscle twitching or small jerks of the face or limbs also occur, sometimes contributing to misdiagnosis. 2, 5Patients typically sense the onset of an episode, allowing them to sit or brace themselves before its occurrence, thus reducing the risk of injury, although in one survey, up to half of patients reported some kind of injury from their cataplexy. 2Duration of a cataplectic assault generally lasts from a few Biotinyl tyramide seconds to several minutes. However , more commonly after the sudden discontinuation of antidepressant medication (tricyclic antidepressants [TCAs], serotonin reuptake inhibitors [SSRIs], or serotonin-norepinephrine reuptake inhibitor [SNRI]), attacks of cataplexy typically are more frequent and/or more intense (rebound phenomena) and can last up to several hours, at which time they are designated as status cataplecticus. 7, 8Frequency of episodes is variable, ranging from <1 episode per year to several per day, but most patients have several episodes per week. 2, 5, 6, 9 with cataplexy is a sleep disorder that is traditionally characterized by a symptom pentad that Biotinyl tyramide includes, in addition to cataplexy, excessive daytime sleepiness (EDS), sleep paralysis, hypnagogic hallucinations, and disrupted nighttime sleep. 10Narcolepsy with cataplexy is estimated to affect 0. 03% to 0. 05% from the general populace, 11and onset occurs typically in childhood or adolescence. 6, 12Although EDS is present in all patients with narcolepsy and is often the initial showing symptom, cataplexy occurs in ~70% of patients; a few, 13cataplexy is considered pathognomonic intended for narcolepsy and after sleepiness is the primary behavioral marker. The third edition from the International Classification of Sleep Disorders (ICSD-3) classifies narcolepsy as either type 1 or type 2, with Biotinyl tyramide the presence of cataplexy incorporated into the definition of type 1 . 13Type 1 narcolepsy is formally defined in the ICSD-3 as EDS that persists intended for 3 months with positive electrophysiological sleep studies that includes the finding of an average sleep-onset latency 8 minutes on the MSLT following a nocturnal polysomnogram that was negative for any comorbid sleep disorders, and two or more sleep-onset rapid eye movement (REM) periods on the MSLT (one of these sleep-onset REM periods may come from the preceding nocturnal polysomnogram) with clear historic evidence of cataplexy or low or absent levels of hypocretin/orexin in cerebrospinal fluid (CSF) along with the positive sleep studies. 13Hypocretin-1 GRIA3 and hypocretin-2, also called orexin A and orexin B, respectively, are peptide neurotransmitters that facilitate wakefulness and enhance arousal mechanisms as well as stabilizing REM and non-REM sleep says. 14, 15Type 2 narcolepsy, or narcolepsy without cataplexy, is defined as EDS persisting intended for 3 months, a positive result on the.